

Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

Jurkat E6.1

RRID:CVCL_0367

Type: Cell Line

Proper Citation

RRID:CVCL_0367

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0367

Proper Citation: RRID:CVCL_0367

Description: Cell line Jurkat E6.1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood T acute lymphoblastic leukemia

Defining Citation: [PMID:7592872](#), [PMID:8316623](#), [PMID:9707173](#), [PMID:10468210](#), [PMID:10832058](#), [PMID:11416159](#), [PMID:11481229](#), [PMID:11669127](#), [PMID:15472075](#), [PMID:18842727](#), [PMID:20215515](#), [PMID:23933134](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26546556](#), [PMID:26589293](#), [PMID:28464451](#), [PMID:29739316](#), [PMID:32938764](#)

Comments: Anecdotal: Have been flown in space on shuttle flights STS-76, STS-80 and STS-95 to study apoptosis and cytoskeleton modifications (PubMed=9707173; PubMed=10832058; PubMed=11481229; PubMed=11669127)., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Jurkat E6.1

Synonyms: JurkatE6-1, Jurkat E6-1, Jurkat, Clone E6-1, Jurkat Clone E6-1, Jurkat (clone E6-1), JURKAT E-6.1, JURKAT E-61, Jurkat-CloneE61, Jurkat-E6, Jurkat E6, J.E6-1, E6-1, Jurkat J6

Cross References: BTO:BTO_0001948, CLO:CLO_0007044, CLO:CLO_0007045, MCCL:MCC:0000260, CLDB:cl2962, CLDB:cl5213, ArrayExpress:E-MTAB-2706, ATCC:TIB-152, BCRC:60424, BCRJ:0125, BEI_Resources:ARP-177, BioSample:SAMN03472194, cancercellines:CVCL_0367, CCRID:1101HUM-PUMC000075, CCRID:1101HUM-PUMC000348, CCRID:1102HUM-NIFDC00049, CCRID:3101HUMSCSP513, CCRID:3101HUMTCHU123, CCRID:4201HUM-CCTCC00094, CCTCC:GDC0094, Cell_Model_Passport:SIDM01244, ChEMBL-Cells:ChEMBL4295390, ChEMBL-Targets:ChEMBL4296446, CLS:300223, Cosmic:913419, ECACC:88042803, EGA:EGAS00001000610, ENCODE:ENCBS407ENC, ENCODE:ENCBS429ENC, ENCODE:ENCBS550BVM, ENCODE:ENCBS551ZKL, ENCODE:ENCBS606GXJ, ENCODE:ENCBS661UFZ, ENCODE:ENCBS732UVO, ENCODE:ENCBS755XWL, GEO:GSE101101, GEO:GSM472928, GEO:GSM510511, GEO:GSM827151, GEO:GSM923424, GEO:GSM945267, GEO:GSM945268, IZSLER:BS TCL 110, KCB:KCB 94008YJ, KCLB:40152, LINCS_LDP:LCL-1030, MetaboLights:MTBLS789, NCBI_Iran:C121, PharmacDB:Jurkat_Clone_E61_713_2019, PRIDE:PRD000345, PRIDE:PXD000148, PRIDE:PXD000589, PRIDE:PXD002871, PRIDE:PXD004415, PRIDE:PXD010176, PRIDE:PXD032302, Progenetix:CVCL_0367, PubChem_Cell_line:CVCL_0367, TOKU-E:2081, Ubigen:YC-D012, Wikidata:Q54899132

ID: CVCL_0367

Hierarchy: cvcl_0065

Record Creation Time: 20220427T220653+0000

Record Last Update: 20260920T004242+0000

Ratings and Alerts

No rating or validation information has been found for Jurkat E6.1.

No alerts have been found for Jurkat E6.1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 661 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell reports, 45(1), 116796.

de Blas A, et al. (2026) Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. Cancer research, 86(12), 2896.

Zhao Z, et al. (2026) Topical delivery of high-drug-loading nanoparticle gels for psoriasis treatment. *Journal of nanobiotechnology*, 24(1).

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. *Molecular cell*, 86(5), 917.

Kwon E, et al. (2026) An extracellular, optogenetic antibody platform for stimulus-gated antigen recognition and modulation of cell behavior. *Cell chemical biology*, 33(6), 848.

Rush JS, et al. (2026) Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity. *Cell*, 189(5), 1356.

Frost IM, et al. (2026) Membrane repair following filtiporation-induced cell permeabilization. *iScience*, 29(1), 114317.

Jagannathan NS, et al. (2026) Dynamic estimation of metabolic state during CAR T cell production. *Cell reports methods*, 6(2), 101303.

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. *Cancer cell*, 44(4), 858.

Rathore U, et al. (2026) Systematic discovery of pro- and anti-HIV host factors in primary human CD4⁺ T cells. *Cell*, 189(12), 3651.

Pacini G, et al. (2026) Contribution of endosomal proteins EHD1 and EHD4 to the HIV-1 replication cycle. *The FEBS journal*.

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4⁺ memory. *iScience*, 29(5), 115593.

Yan X, et al. (2026) KRASG12/13 mutation modulates CRC outcomes via disrupting positive feedback between macrophage and CD4⁺ T cell. *iScience*, 29(1), 114402.

Yatim A, et al. (2026) Human LFA-1 governs T cell immune surveillance of the skin. *Science immunology*, 11(116), eadz8360.

Luque M, et al. (2026) Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. *Neoplasia (New York, N.Y.)*, 78, 101318.

Wang Y, et al. (2026) Tuning the sensitivity of mechanosensory receptors through histidine scanning. *Cell*, 189(6), 1680.

Rubin AJ, et al. (2026) Disordered protein LAT encodes relative levels of signaling pathways in T cell activation. *Science (New York, N.Y.)*, 392(6797), eads6847.

Gunnels TF, et al. (2026) CELLISA - a cell-cell binding assay for evaluation of nanovesicle targeting proteins. *bioRxiv : the preprint server for biology*.

Hu X, et al. (2026) Genetic identification of the Fc γ R complex: TR γ V12-4 as the IgD-binding domain targeted for immunotherapy in rheumatoid arthritis. *Journal of advanced research*.

Shao N, et al. (2026) A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. *Microsystems & nanoengineering*, 12(1).